Skip to main navigation Skip to search Skip to main content

Safety, Pharmacokinetics, and Pharmacodynamics of the Insulin-Like Growth Factor Type 1 Receptor Inhibitor Figitumumab (CP-751, 871) in Combination with Paclitaxel and Carboplatin

  • D.D. Karp
  • , M.N. Pollak
  • , R.B. Cohen
  • , P.D. Eisenberg
  • , P. Haluska
  • , D. Yin
  • , A. Lipton
  • , L. Demers
  • , K. Leitzel
  • , M.L. Hixon
  • , Leonardus Wendelinus Mathias Marie Terstappen
  • , L. Garland
  • , L.G. Paz-Ares
  • , F. Cardenal
  • , A. Gualberto

Research output: Contribution to journalArticleAcademicpeer-review

Original languageUndefined
Pages (from-to)1397-1403
JournalJournal of thoracic oncology
Volume4
Issue number11
DOIs
Publication statusPublished - 2009

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • METIS-259828

Cite this